{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:24:19Z","timestamp":1782962659624,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02232-y","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:16:09Z","timestamp":1773472569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-5908","authenticated-orcid":false,"given":"Serap","family":"Cetiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"2232_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/dc24-SINT","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes\u20142024. Diabetes Care. 2024;47:1\u2013350. https:\/\/doi.org\/10.2337\/dc24-SINT.","journal-title":"Diabetes Care"},{"key":"2232_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1055\/s-0043-103969","volume":"125","author":"LA Leiter","year":"2017","unstructured":"Leiter LA, Nauck MA. Efficacy and safety of GLP-1 receptor agonists across the spectrum of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2017;125:419\u201335.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2232_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819\u201337.","journal-title":"Cell Metab"},{"key":"2232_CR4","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131\u201357.","journal-title":"Gastroenterology"},{"key":"2232_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ. Cardioprotective and vasodilatory actions of GLP- 1 receptor are mediated through GLP-1R-dependent and -independent pathways. Circulation. 2008;117:2340\u201350.","journal-title":"Circulation"},{"key":"2232_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","volume":"403","author":"I Merchenthaler","year":"1999","unstructured":"Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and GLP-1 receptor mRNAs in the rat CNS. J Comp Neurol. 1999;403:261\u201380.","journal-title":"J Comp Neurol"},{"key":"2232_CR7","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke C, Heller RS, Kirk RK, \u00d8rskov C, Reedtz-Runge S, et al. GLP-1 receptor localization in monkey and human tissue. Endocrinology. 2014;155:1280\u201390.","journal-title":"Endocrinology"},{"key":"2232_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, et al. Glucagon-like peptide-1 (GLP-1). Mol Metab. 2019;30:72\u2013130.","journal-title":"Mol Metab"},{"key":"2232_CR9","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Printer","year":"2022","unstructured":"Printer DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351.","journal-title":"Mol Metab"},{"issue":"Suppl 2","key":"2232_CR10","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.2337\/dc11-s231","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber AJ. Long-acting glucagon-like peptide-1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279\u201384.","journal-title":"Diabetes Care"},{"key":"2232_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1900\/RDS.2008.5.73","volume":"5","author":"RE Pratley","year":"2008","unstructured":"Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008;5:73\u201394.","journal-title":"Rev Diabet Stud"},{"key":"2232_CR12","volume-title":"Trulicity\u00ae (Dulaglutide) Injection, Prescribing Information","author":"Indianapolis","year":"2022","unstructured":"Eli Lilly and Company, Indianapolis. Trulicity\u00ae (Dulaglutide) Injection, Prescribing Information. USA: IN; 2022."},{"key":"2232_CR13","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Dulaglutide monotherapy versus metformin in type 2 diabetes (AWARD-3). Diabetes Care. 2014;37:2168\u201376.","journal-title":"Diabetes Care"},{"key":"2232_CR14","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58:7370\u201380.","journal-title":"J Med Chem"},{"key":"2232_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2021","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2021;33:159\u201366.","journal-title":"Trends Cardiovasc Med"},{"key":"2232_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcder J, Andreassen C, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN-7). Lancet Diabetes Endocrinol. 2018;6:275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2232_CR17","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/jdi.14000","volume":"14","author":"T Iijima","year":"2023","unstructured":"Iijima T, Shibuya M, Ito Y, Terauchi Y. Effects of switching from liraglutide to semaglutide or dulaglutide. J Diabetes Investig. 2023;14:1423\u201331.","journal-title":"J Diabetes Investig"},{"key":"2232_CR18","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2337\/db24-0861","volume":"74","author":"D Shantaram","year":"2025","unstructured":"Shantaram D, Rima XY, Bradley D, Kuo T, Moreno C, et al. Dulaglutide attenuates hepatic steatosis via weight-independent mechanisms. Diabetes. 2025;74:1512\u201324.","journal-title":"Diabetes"},{"key":"2232_CR19","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.dsx.2023.102849","volume":"17","author":"S Bandyopadhyay","year":"2023","unstructured":"Bandyopadhyay S, Das S, Samajdar SS, Joshi SR. Semaglutide in NAFLD\/NASH: a systematic review & meta-analysis. Diabetes Metab Syndr. 2023;17:102849.","journal-title":"Diabetes Metab Syndr"},{"key":"2232_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"2232_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/dom.13120","volume":"20","author":"JB Hjerpsted","year":"2018","unstructured":"Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T. Semaglutide improves postprandial glucose and lipid metabolism. Diabetes Obes Metab. 2018;20:610\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"2232_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00592-022-01936-6","volume":"59","author":"U Di Folco","year":"2022","unstructured":"Di Folco U, Vallecorsa N, Nardone MR, Pantano AL, Tubili C. Semaglutide effects on cardiovascular risk factors and eating behavior. Acta Diabetol. 2022;59:1287\u201394.","journal-title":"Acta Diabetol"},{"key":"2232_CR23","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"2232_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2337\/dc16-2684","volume":"40","author":"WM Steinberg","year":"2017","unstructured":"Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, et al. Impact of liraglutide on amylase, lipase and acute pancreatitis. Diabetes Care. 2017;40:839\u201348.","journal-title":"Diabetes Care"},{"key":"2232_CR25","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/MPA.0000000000000229","volume":"43","author":"WM Steinberg","year":"2014","unstructured":"Steinberg WM, Nauck MA, Zinman B, Bergenstal R, Lakshmanan M, et al. LEADER-3: lipase and amylase activity baseline data. Pancreas. 2014;43:1223\u201331.","journal-title":"Pancreas"},{"key":"2232_CR26","first-page":"8740","volume":"27","author":"S Cetiner","year":"2023","unstructured":"Cetiner S. A single-center study on biochemical effect and clinical effectiveness of liraglutide in Turkish patients. Eur Rev Med Pharmacol Sci. 2023;27:8740\u201353.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02232-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02232-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02232-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:52:16Z","timestamp":1774522336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02232-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02232-y","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Bak\u0131rk\u00f6y Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey (Approval number: 2024\/374; Date: 25 December 2024)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Informed consent forms were obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}